The facile preparation of primary and secondary amines via an improved Fukuyama–Mitsunobu procedure. Application to the synthesis of a lung-targeted gene delivery agent
Vesicular Monoamine Transporter-2 Ligands and Their Use in the Treatment of Psychostimulant Abuse
申请人:University of Kentucky Research Foundation
公开号:US20170304227A1
公开(公告)日:2017-10-26
The present invention relates to methods of treatment of a disease or pathology of the central nervous system, an eating disorder, or substance use disorder, drug dependence/abuse and withdrawal therefrom comprising administering at least one N-phenylalkyl amphetamine derivative and pharmaceutical compositions comprising at least one N-phenylalkyl amphetamine derivative to an individual in need thereof.
Medicinal compounds from β-phenylisopropylamine derivatives. VIII. Dependence of pharmacological activity upon structure in a series of β-phenylisopropylamine derivatives
作者:N. I. Kudryashova、N. A. Novikova
DOI:10.1007/bf00760702
日期:1984.4
described earlier: ll-Vl [i], Vll-Xl [2], XII [3], XIV and XV [4]. The dihydrochloride of compound XIII was described in [5]. It was prepared by reduction of the 8-phenylisopropylamide of 4,4'-dinitrodiphenylacetic acid with iron in acetic acid. However, the authors did not isolate the base, and indicated that it was unstable and rapidly darkened in air. In the present work, we studied hydrazine hydrate
Programmable Amine Synthesis via Iterative Boron Homologation
作者:Qiqiang Xie、Rui Zhang、Guangbin Dong
DOI:10.1002/anie.202307118
日期:2023.8.28
Programmable amine synthesis is realized through sequential insertion of nitrogen and carbon atoms into boronate C−B bonds. This strategy is enabled by a new nitrenoid reagent, which allows for direct formation of aminoboranes from aryl or alkyl boronates via N-insertion.
Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse
申请人:University of Kentucky Research Foundation
公开号:US10668030B2
公开(公告)日:2020-06-02
The present invention relates to methods of treatment of a disease or pathology of the central nervous system, an eating disorder, or substance use disorder, drug dependence/abuse and withdrawal therefrom comprising administering at least one N-phenylalkyl amphetamine derivative and pharmaceutical compositions comprising at least one N-phenylalkyl amphetamine derivative to an individual in need thereof.